Marstacimab
Modify Date: 2024-01-02 13:29:56
Marstacimab structure
|
Common Name | Marstacimab | ||
|---|---|---|---|---|
| CAS Number | 1985638-39-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MarstacimabMarstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2]. |
| Name | Marstacimab |
|---|
| Description | Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Marstacimab (20，50 和 100 nmol/L) 降低血友病患者的全血样本中的玉米胰蛋白酶 (CT)[1]。 Marstacimab (16 μg/mL) 可缩短体外培养的人非血友病去血小板血浆样本的滞后时间并增加凝血酶生成[2]。 Marstacimab (16 μg/mL) 在体外可提高血友病 A 和血友病 B 血浆样本中凝血酶峰值[2]。 |
| In Vivo | Marstacimab (0.5 mg/kg；静脉注射) 不影响小鼠急性出血模型的血流情况[2]。 Animal Model: Acute bleeding hemophilia A mouse models[2] Dosage: 0.5 mg/kg Administration: Intravenous injection, 0.5 mg/kg, once, before tail clip Result: Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg. |
| References |
| No Any Chemical & Physical Properties |